ARIAD

February 16, 2017

ARIAD Seeks European Authorization of Brigatinib as Lung Cancer Treatment

News

ARIAD Pharmaceuticals has asked the European Union to approve the marketing of its investigational therapy brigatinib for lung cancer. The European Medicines Agency (EMA) will recommend whether the EU should ... Read more

November 14, 2016November 29, 2016

ARIAD Launches Inaugural ALK-positive NSCLC Awareness Day

News

ARIAD Pharmaceuticals recently launched an awareness day for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC), the first time a day was specifically focused on the condition. The ... Read more

November 1, 2016

Ariad’s New Drug Application of Brigatinib for NSCLC to Be Reviewed by FDA

News

The U.S. Food and Drug Administration (FDA) will review Ariad‘s new drug application (NDA) for brigatinib, an investigational therapy for patients with non-small cell lung cancer (NSCLC) who have progressed following ... Read more